CYP 5.17% 27.5¢ cynata therapeutics limited

Ann: Investor Webinar Presentation, page-9

  1. 791 Posts.
    lightbulb Created with Sketch. 315
    The DFU information was released with the CR presentation back in April (slides 17-19): https://cdn-api.markitdigital.com/apiman-gateway/CommSec/commsec-node-api/1.0/event/document/1410-02652273-7NSCRSUGSJJKGVONAOHJ1S31OE/pdf?access_token=0007YUZeQM9jdt0x5ryaOwTUcoAr

    What is notable is the inclusion of more preclinical data demonstrating Cymerus MSCs reduction of heterogeneity compared to tissue-derived MSCs. Heterogeneity is a major hurdle to the commercialisation of MSC therapies. As the FDA noted in the ODAC briefing document for Rem-L, in the absence of outstanding results from a well-controlled clinical trial, the therapy at the very least needs to have a mechanism of action (MOA) consistent with what is observed in laboratory testing. If the underlying treatment is not consistent on a batch-to-batch basis, that makes it difficult to achieve. Fortunately, a single blood donation is the foundation for 21 million clinical doses of Cymerus MSCs, greatly improving the probability that the clinical MOA will closely match what is expected.
    Last edited by truss20: 20/09/23
 
watchlist Created with Sketch. Add CYP (ASX) to my watchlist
(20min delay)
Last
27.5¢
Change
-0.015(5.17%)
Mkt cap ! $49.39M
Open High Low Value Volume
29.0¢ 29.0¢ 26.0¢ $30.21K 109.6K

Buyers (Bids)

No. Vol. Price($)
1 63362 26.5¢
 

Sellers (Offers)

Price($) Vol. No.
28.0¢ 33487 1
View Market Depth
Last trade - 15.51pm 21/05/2024 (20 minute delay) ?
Last
27.5¢
  Change
-0.015 ( 0.00 %)
Open High Low Volume
29.0¢ 29.0¢ 26.5¢ 46774
Last updated 15.51pm 21/05/2024 ?
CYP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.